[Significance of orotic acid and purine bases in the prevention of decompensation of the hyperthrophic heart].
D000225:Adenine / Q000627:therapeutic use*; D000311:Adrenal Glands / Q000032:analysis; D000818:Animals; D001024:Aortic Valve Stenosis; D001923:Brain Chemistry / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D006332:Cardiomegaly; D005260:Female; D006333:Heart Failure / Q000517:prevention & control*; D007042:Hypoxanthines / Q000627:therapeutic use*; D007668:Kidney / Q000032:analysis; D008099:Liver / Q000032:analysis; D008168:Lung / Q000032:analysis; D008297:Male; D009206:Myocardium / Q000032:analysis; D009210:Myofibrils / Q000187:drug effects; D009696:Nucleic Acids / Q000032:analysis; D009963:Orotic Acid / Q000627:therapeutic use*; D010179:Pancreas / Q000032:analysis; D011506:Proteins / Q000032:analysis; D051381:Rats; D013154:Spleen / Q000032:analysis; D013268:Stimulation, Chemical; D014970:Xanthines / Q000627:therapeutic use*
D007042:Hypoxanthines; D009696:Nucleic Acids; D011506:Proteins; D014970:Xanthines; D009963:Orotic Acid; D000225:Adenine
Znachenie orotovoĭ kisloty i purinovykh osnovaniĭ v profilaktike dekompensatsii gipertrofirovannogo serdtsa.